



Italian Journal of Gynæcology & Obstetrics

September 2025 - Vol. 37 - N. 3 - Quarterly - ISSN 2385 – 0868

Serum human chorionic gonadotropin and ultrasound criteria in women with successful expectant management of tubal ectopic pregnancies: a retrospective cohort study

Esraa Talat ¹, Amgad Abo Gamra ², Mohamed Sweed ^{2,3}, Radwa Ali ^{2,*}

¹ Om El-Masryen General Hospital, Cairo, Egypt.

² Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

³ Department of Obstetrics and Gynecology, Faculty of Medicine, Badr University, Cairo, Egypt.

ARTICLE INFO

History

Received: 26 October 2024

Received in revised form: 24 December 2024

Accepted: 08 January 2025

Available online: 30 September 2025

DOI: 10.36129/jog.2025.211

Key words

Ectopic pregnancy; expectant management; human chorionic gonadotropin; tubal pregnancy.

*Corresponding author: Radwa Ali, Associate Professor. Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Abbassia, 11566 Cairo, Egypt.
Email: aliradwa392@gmail.com.
ORCID: 0009-0005-8016-9459.

ABSTRACT

Objective. To identify different variables associated with successful expectant management of tubal ectopic pregnancies.

Materials and Methods. A retrospective analysis was performed at Ain Shams University Maternity Hospital, examining the medical records of 88 cases of tubal ectopic pregnancy that were successfully managed through expectant management. Data regarding ultrasonographic criteria, peak serum β -hCG (human chorionic gonadotropin) levels, subsequent β -hCG trends during follow-up, and the duration (in days) required for resolution were analysed.

Results. The mean diameter of the ectopic mass was 30.0 ± 9.73 mm and 26 ± 8.9 for the vertical and horizontal diameters, respectively. Twelve (18.5%) cases had no free fluid in the Douglas pouch. The median initial serum β -hCG concentration was 724.20 IU/L (IQR 361.95-1252.00, with the highest initial serum β -hCG concentration was 4617 IU/L).

The median time required for resolution was 15.0 days (IQR 12.0-18.0), whereas the median duration of hospitalization was 4.0 days (IQR 3-7.0).

Conclusions. Clinically stable women with tubal EP, ectopic mass up to 50 mm and those with variable degrees of hemoperitoneum and variable levels of β -HCG (up to 4617) can achieve successful expectant management. These findings provide valuable insights into identifying candidates suitable for expectant management in cases of tubal EP.

INTRODUCTION

Expectant management (EM) has gained growing recognition as an acceptable alternative for management of tubal ectopic pregnancies (EP). This strategy entails careful monitoring of EP without resorting to immediate medical or surgical intervention.

This “wait and watch” approach allows patients to avoid the potential complications associated with surgical procedures and the adverse effects of pharmacological treatments [1, 2].

The aim of EM is to observe whether the tubal EP will resolve spontaneously, however; the main challenge for healthcare providers in embracing this

line of treatment lies in the absence of a consensus regarding the selection criteria of women eligible for EM [3].

To date, there is a significant difference in the recommendations across the literature along with the absence of standardized selection criteria for women eligible for EM. Nonetheless, most of the studies reported that eligible women should be willing and able to attend for follow-up, have minimal pain, have low or declining serum β -hCG levels. The success rates for EM are highly variable, ranging from 57% to 100%, and are strongly dependent on case selection [4].

The National Institute for Health and Care Excellence suggested that EM can be offered for those with serum hCG levels of 1,000 IU/L or less and may be considered for women with serum hCG levels above 1,000 IU/L but less than 1,500 IU/L [2]. In contrast, the American College of Obstetricians and Gynecologists did not specify a serum β -hCG level cut-off for offering EM but noted an 88% success rate when the initial serum β -hCG level is below 200 IU/L [5]. Moreover, Tulandi advised against EM for cases of EP with the serum hCG level exceeds 200 IU/mL at any point during follow-up or if levels are rising [6].

A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy and safety of EM for the treatment of tubal EP. The findings did not provide sufficient evidence to ascertain whether significant differences exist between EM and methotrexate in stable patients with serum β -hCG levels below 1,500 IU/L regarding the resolution of tubal EP, the avoidance of surgical intervention, or the duration required for tubal EP resolution [7].

The aim of this study was to assess the initial serum β -hCG levels and ultrasonographic criteria in women who had successful EM of tubal EP. This data can serve as a basis for establishing selection criteria for EM and may provide guidance for healthcare professionals in the management of tubal EP through expectant approaches.

MATERIALS AND METHODS

This retrospective study was carried out at Ain-Shams University Maternity Hospital, analysing the medical records of 88 tubal ectopic pregnancies that were successfully managed expectantly between January 2016 and December 2020. The women

included in the study were those who were hemodynamically stable, with a confirmed diagnosis of tubal ectopic pregnancy based on ultrasound, showing no foetal heartbeats, no significant pelvic pain, and a serum hCG level of less than 5000 IU/L. The initial management approach offered to the patient, following comprehensive counselling, was expectant management.

In the process of planning the study, our original objective was to exclude cases involving hemoperitoneum. However, upon reviewing the medical records, we discovered that the majority of cases contained varying levels of fluid in the Douglas pouch. As a result, these cases were incorporated into the analysis.

The data extracted from the patients' medical records included maternal age, parity, duration of amenorrhea, history of prior abortion or ectopic pregnancy, presenting symptoms, clinical examination findings, and ultrasonographic results at both the initial presentation and at discharge.

Ultrasound findings included the measurements of the vertical and horizontal diameters of the ectopic masses and their morphological appearance that was graded according to Dooley *et al.*, gestational sac containing an embryo with no visible cardiac activity, gestational sac containing only a yolk sac with no visible embryo, empty gestational sac with no visible additional structures, and solid homogenous mass [8]. The presence of free pelvic fluid or hemoperitoneum and the measurements of the endometrial thickness at times of admission and discharge were reviewed.

β -hCG levels were documented during the initial visit and throughout the follow-up period. Initially, β -hCG measurements were taken at 48-hour intervals, with the frequency decreasing to once a week after confirming an adequate decline, defined as reaching non-pregnant levels of less than 10 IU/L. The primary outcome was the resolution of hCG (upper limit of qualitative hCG levels associated with successful EM of ectopic pregnancy). Secondary outcomes included ultrasonographic markers indicative of successful EM, the time required for resolution of the ectopic pregnancy, the length of hospital stay, and reproductive outcomes following EM of ectopic pregnancy.

Ethical consideration

The study was approved by the Ethical and Research Committee of the Council of Obstetrics and Gynecology Department, and Faculty of Medici-

Table 1. Basic demographic and initial clinical characteristics of the study population.

| Demographic variables | | |
|--|---------------|--|
| Age (Years) | | |
| Mean ± SD | 28.94 ± 5.36 | |
| Period of amenorrhea (days) | | |
| Mean ± SD | 46.83 ± 8.6 | |
| Parity n (%) | | |
| 0 | 20 (22.7%) | |
| 1 | 20 (22.7%) | |
| 2 | 26 (29.5%) | |
| 3 or more | 22 (25.0%) | |
| Previous Abortions n (%) | 24 (27.2%) | |
| Previous Ectopic pregnancy n (%) | 3 (3.4%) | |
| Clinical Presentation n (%) | | |
| Pain | 13 (15.1%) | |
| Vaginal Bleeding | 3 (3.5%) | |
| Pain and vaginal bleeding | 6 (7.0) | |
| Referred from another unit | 64 (74.4%) | |
| Systolic blood pressure mmHg (Mean ± SD) | 114.28 ± 6.45 | |
| Diastolic blood pressure (Mean ± SD) | 73.45 ± 6.11 | |
| Pulse b/m (Mean ± SD) | 84.88 ± 6.44 | |

ne Ain Shams University Ethical Research Committee (FMASU ERC) (FMASU M S 304/2021) on 2/6/2021. An informed consent was obtained from each participant upon hospital admission as per the administration protocols and the hospital administration consent to review the needed data record was obtained. The study was reported in accordance with STROBE guidelines for reporting observational studies.

RESULTS

Between January 2016 to December 2020 556 women were diagnosed with a tubal ectopic pregnancy in Ain-Shams University Maternity Hospital and 88 (15.8%) of them underwent successful EM. The mean age of women who had successful EM was 28.94 ± 5.36 years, with mean period of amenorrhea 46.83 ± 8.6 days (Table 1).

Regarding the sonographic findings at admission, 53 (81.5%) women showed solid tubal mass, the mean diameter of the ectopic mass was 30.0 ± 9.73 mm and 26 ± 8.9 for the vertical and horizontal diameters, respectively. Only 12 (18.5%) of the cases had no free fluid in the Douglas pouch (Table 2).

Table 2. Participants' ultrasound findings at initial presentation.

| Ultrasound variables | | |
|---|------------------|--|
| Endometrial Thickness (mm) | | |
| Mean ± SD | 8.0 ± 2.95 | |
| Median (IQR) | 8.0 (6.0-9.0) | |
| (Minimum- Maximum) | (4.0-18.0) | |
| Size of Ectopic mass (vertical diameter) (mm) | | |
| Mean ± SD | 30.0 ± 9.73 | |
| Median (IQR) | 30.0 (23.0-37.0) | |
| (Minimum- Maximum) | (14.0-50.0) | |
| Size of Ectopic mass (horizontal diameter) (mm) | | |
| Mean ± SD | 26 ± 8.9 | |
| Median (IQR) | 25.0 (20.0-30.0) | |
| (Minimum- Maximum) | (11.0-50.0) | |
| Ectopic mass measuring ≥ 35 mm | 24 (37.5%) | |
| No free fluid in Douglas pouch | 12 (18.5%) | |
| Grading | | |
| Solid mass | 53 (81.5%) | |
| Gestational Sac without foetal pole | 11 (16.9%) | |
| Gestational Sac with foetal pole | 1 (1.5%) | |

Table 3. Criteria of serum β-hCG concentrations at the initial visit.

| Criteria | | |
|--|-------------------------|--|
| Serum β-hCG concentrations at the initial visit (IU/L) | | |
| Median (IQR) | 724.20 (361.95-1252.00) | |
| Minimum | 55.60 | |
| Maximum | 4617.00 | |
| Serum β-hCG categorization (IU/L) n (%) | | |
| < 200 | 13 (14.8%) | |
| 2,00-1,000 | 43 (48.9%) | |
| 1,001-1,500 | 15 (17.0%) | |
| 1,501-2,000 | 8 (9.1%) | |
| 2,001-4,000 | 7 (8.0%) | |
| > 4,000 | 2 (2.3%) | |
| Serum β-hCG trend over 48 hours n (valid%) | | |
| Decreasing ≥15% | 60 (85.7%) | |
| Decreasing <15% | 9 (12.9%) | |
| Increasing | 1 (1.4%) | |
| Serum β-hCG at 48 hour/serum β-hCG on admission ratio n (valid%) | | |
| < 0.8 | 53 (75.7%) | |
| ≥ 0.8 | 17 (24.3%) | |

The median initial serum β-hCG concentration was 724.20 IU/L (IQR 361.95-1252.00). The highest recorded initial serum β-hCG concentration was 4617 IU/L (Table 3).

The median time interval from diagnosis to resolution was 15.0 days (IQR 12.0-18.0) and the median

Table 4. Duration of follow up, hospitalization, and reproductive outcomes.

| Variables | |
|------------------------------------|------------------|
| Duration of follow up (days) | |
| Mean \pm SD | 16.5 \pm 7.4 |
| Median (IQR) | 15.0 (12.0-18.0) |
| (Minimum- Maximum) | (4.0-45.0) |
| Duration of hospitalization (days) | |
| Mean \pm SD | 5.2 \pm 3.6 |
| Median (IQR) | 4.0 (3-7.0) |
| (Minimum- Maximum) | (1.0-20.0) |
| Reproductive outcomes n (%) | |
| No pregnancy | 23 (26.1%) |
| Normal pregnancy | 14 (15.9%) |
| Ectopic pregnancy | 2 (2.3%) |
| Not seeking fertility | 49 (55.7%) |

duration of hospital stay was 4.0 days (IQR 3-7.0) (Table 4).

DISCUSSION

Ectopic pregnancy can be a life-threatening obstetrical emergency leading to catastrophic intra-abdominal haemorrhage that could also occur with spontaneous rupture of uterine vessels, or with uterine rupture [9,10].

A small proportion of women with EP who are at minimal risk of tubal rupture may be considered for EM. However, there is no agreement among various professional societies regarding the clinical criteria that reliably predict the success of EM for tubal EP. The Society of Obstetricians and Gynecologists of Canada (SOGC) suggests offering EM if the initial β -hCG $<$ 1,000 IU/L and decreasing (\geq 15%-20%) over 48 hours with no significant hematosalpinx, no foetal heart rate, and no significant free fluid [11].

The criteria reported by the National Institute for Health and Care Excellence included clinically stable women with a tubal ectopic pregnancy measuring less than 35 mm with no visible heartbeat on transvaginal ultrasound scan and no hemoperitoneum with serum β -hCG levels of 1000 IU/L or less. EM can be considered if serum β -hCG levels above 1000 IU/L and below 1500 IU/L [2].

American College of Obstetricians and Gynecologists (ACOG) reported that criteria for EM eligibility includes asymptomatic women without evidence of rupture or haemodynamic instability

with objective evidence of resolution *i.e.*, declining or plateauing β -hCG levels. ACOG does not specify a particular β -hCG threshold for initiating EM, but noted 88% success rate if EM offered in cases with the initial serum β -hCG level below 200 IU/l [5].

The initial serum β -hCG is the most reliable predictor of the eventual outcome of EM. Higher initial β -hCG levels are associated with a lower likelihood of spontaneous pregnancy resolution. Different studies suggested different maximum β -hCG thresholds beyond which EM may not be safe nor effective.

In the current study, the maximum initial serum β -hCG concentration was 4617 IU/L. The median initial concentration was 724.20 IU/L (IQR 361.95-1,252.00), with 13 (14.8%), 43 (48.9%) and 15 (17.0%) women successfully managed expectantly had initial serum β -hCG concentration $<$ 200 IU/L, 200-1,000 IU/L, and 1,000-1,500 IU/L, respectively. Similarly, Helmy *et al.* [12], found that among the 161 patients who had successful expectant management the mean initial serum β -hCG was 488 IU/L (range from 41 to 4883 IU/L). In their clinical protocol for EM, Mavrellos and colleagues offered expectant management for women with an initial serum β -hCG level of $<$ 1,500 IU/L [13].

Rodrigues *et al.* found no role for EM in cases with initial serum β -hCG exceeds 3,000 IU/l. In their study, 67% of the cases with an initial hCG level above 2,000 IU/l developed symptoms during the follow up [14].

The decline in serum β -hCG level is considered a reliable predictor of successful EM. The serum β -hCG at 48 hour / serum β -hCG at 0-hour ratio of less than 0.8 was associated with an overall success rate of 72% [15]. In the present study, this ratio was found to be below 0.8 in 53 women, accounting for 75.7% of the participants.

Our analysis revealed that 24 cases (37.5%) exhibited an ectopic mass with a size of \geq 35 mm, with the largest vertical or horizontal diameter reaching 50 mm. Additionally, 81.5% of the cases involved solid masses. Furthermore, only 12 cases (18.5%) demonstrated an absence of free fluid in the Douglas pouch.

Mavrellos and colleagues found that solid heterogeneous mass was the main ultrasound finding in 70.2% of cases successfully managed expectantly with the median size of the mass 14.0 mm (11.4-18.25) [13]. In contrast, Helmy *et al.* reported the

successful EM in cases with a tubal mass measuring up to 57 mm [12].

The guidelines set by the National Institute for Health and Care Excellence (NICE) are commonly applied when selecting women for expectant management [2]; however, in contrast to these recommendations, our findings indicated that 24 (37.5%) women with ectopic mass measuring ≥ 35 mm, and 32 (36.6%) women with β -hCG level $> 1,000$ IU/L could be managed expectantly and avoiding the complications associated with both medical and surgical treatment.

As previously mentioned, the various guidelines recommend against EM in the presence of hemoperitoneum and it was considered an absolute contraindication for methotrexate. In the current study, only 12 (18.5%) of the cases showed no hemoperitoneum. This was in line with Bignardi and Condous, 2009, who reported that the presence of hemoperitoneum was not an absolute contraindication to conservative treatment of EP [16].

This could be explained by the fact that the presence of hemoperitoneum of any degree does not necessarily signify the diagnosis of tubal rupture or indicate hemodynamic instability. Rather, it may indicate a complete tubal abortion with the expulsion of the product of conception outside the fallopian tubes, without associated tubal rupture, accompanied by varying degrees of fluid. This would allow for conservative surgical management and preserving fertility [17]. Moreover, spontaneous hemoperitoneum in pregnancy has been reported in 100 cases within the literature, though the precise pathogenesis remains uncertain. Potential etiological factors, including hemodynamic and hormonal influences, have been suggested [10].

Another advantage of EM is the potential to conceive more quickly compared to women receiving methotrexate, who are typically advised to wait for 3 months [7].

In the current study, 14 women (15.9%) achieved normal pregnancy after EM, and 2 women (2.3%) had recurrent EP.

Previous data reported that EM was associated with the highest cumulative incidence of clinical pregnancy, live birth rate, and the shortest time to achieve an intrauterine pregnancy when compared to medical and surgical treatment [18]. According to Kirk *et al.*, ninety-three percent of cases received EM of suspected EP has shown tubal patency during hysterosalpingography with subsequent intrauterine pregnancy rates of 63-88 percent [19].

Due to the preservation of fertility provided by the conservative approach, trials of conservative management for both tubal and non-tubal ectopic pregnancies (EP) have been explored with varying success rates. In a recent case report and systematic review, Conte and colleagues discussed available treatment options for managing the rare condition of cervical twin pregnancy. They emphasized the lack of standardized criteria for implementing conservative management in such cases. They proposed that transvaginal ultrasound is a reliable and safe method for detecting hemoperitoneum. In their case report, they successfully terminated the pregnancies through dilation and curettage, followed by the placement of an intracervical Foley balloon, thereby preserving the patient's fertility without the need for methotrexate [20].

CONCLUSIONS

Clinically stable women with tubal EP, ectopic mass up to 50 mm and those with variable degrees of hemoperitoneum and variable levels of β -HCG (up to 4,617) can achieve successful expectant management. These findings can be useful for determining which women should undergo expectant management for tubal EP.

Strengths and limitation

The main limitation of this study was the small sample size, also the retrospective nature of the study with some missing data in the medical records, but it opens up interesting openings for pilot and prospective studies. However, challenge the idea that surgery is mandatory in women with a tubal ectopic pregnancy and hemoperitoneum on ultrasound examination represents an interesting finding that could be the scope of future studies. Moreover, documenting the safety of EM in cases with higher β -HCG levels and larger ectopic mass could help in setting different selection criteria in EM clinical guidelines.

COMPLIANCE WITH ETHICAL STANDARDS

Authors' contributions

E.T.: Data curation, formal analysis, investigation, writing – review & editing. A.A.: Conceptualization, formal analysis, methodology, writing – review & editing. M.S.: Conceptualization, methodology, re-

sources, supervision, validation, visualization, writing – review & editing. R.A.: Conceptualization, methodology, resources, supervision, validation, visualization, writing – original draft.

Funding

None.

Study registration

Clinical trials.gov: NCT04975984

Disclosure of interests

The authors declare that they have no conflict of interests.

Ethics approval

The study was approved by the Ethical and Research Committee of the Council of Obstetrics and Gynecology Department, Faculty of Medicine Ain Shams University Ethical Research Committee (FMASU ERC) (FMASU MS 254/2021) on 17/4/2021 and Ethical Committee of the Council of Obstetrics and Gynecology Department.

Informed consent

Informed consent for data collection for research purposes was obtained from all subjects involved in the study.

Data sharing

Data are available under reasonable request to the corresponding author.

REFERENCES

- Mavrellos D, Memtsa M, Helmy S, Derdelis G, Jauniaux E, Jurkovic D. β -hCG resolution times during expectant management of tubal ectopic pregnancies. *BMC Womens Health*. 2015;15:43. doi: 10.1186/s12905-015-0200-7.
- National Institute for Health and Care Excellence (2019): Ectopic pregnancy and miscarriage: diagnosis and initial management (NICE Guideline 126). Available at: www.nice.org.uk/guidance/ng126. Accessed on July 10, 2023.
- Mavrellos D, Nicks H, Jamil A, Hoo W, Jauniaux E, Jurkovic D. Efficacy and safety of a clinical protocol for expectant management of selected women diagnosed with a tubal ectopic pregnancy. *Ultrasound Obstet Gynecol*. 2013;42(1):102-7. doi: 10.1002/uog.12401.
- Elson CJ, Salim R, Potdar N, Chetty M, Ross JA, Kirk EJ. on behalf of the Royal College of Obstetricians and Gynaecologists. Diagnosis and management of ectopic pregnancy. *BJOG Int J Obstet Gynaecol*. 2016;123:e15-e55. doi: 10.1111/1471-0528.14189.
- American College of Obstetricians and Gynecologists' Committee on Practice Bulletins - Gynecology. ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy. *Obstet Gynecol*. 2018;131(3):e91-e103. doi: 10.1097/AOG.0000000000002560.
- Tulandi T. Ectopic pregnancy: Expectant management In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
- Colombo GE, Leonardi M, Armour M, Di Somma H, Dinh T, da Silva Costa F, et al. Efficacy and safety of expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. *Hum Reprod Open*. 2020;2020(4):hoaa044. doi: 10.1093/hropen/hoaa044.
- Dooley W, De Braud L, Memtsa M, Thanatsis N, Jauniaux E, Jurkovic D. Physical resolution of tubal ectopic pregnancy on ultrasound imaging following successful expectant management. *Reproductive BioMedicine Online*. 2020;40(6):880-6.
- Vimercati A, Dellino M, Suma C, Damiani GR, Malvasi A, Cazzato G, et al. Spontaneous Uterine Rupture and Adenomyosis, a Rare but Possible Correlation: Case Report and Literature Review. *Diagnostics*. 2022;12(7):1574. doi: 10.3390/diagnostics12071574.
- Maiorana A, Zaccaria G, Parisi G, Mercurio A, Forlani F. Spontaneous hemoperitoneum in pregnancy due to rupture of uterine vessels in woman with endometriosis: a case report. *Ital J Gynaecol Obstet*. 2024;36(2):191-5 doi: 10.36129/jog.2023.124.
- Po L, Thomas J, Mills K, Zakhari A, Tulandi T, Shuman M, et al. Guideline No. 414: Management of Pregnancy of Unknown Location and Tubal and Nontubal Ectopic Pregnancies. *J Obstet Gynaecol Can*. 2021;43(5):614-30.e1. doi: 10.1016/j.jogc.2021.01.002.
- Helmy S, Mavrellos D, Sawyer E, Ben-Nagi J, Koch M, Day A, et al. Serum Human Chorionic Gonadotropin (β -hCG) Clearance Curves in Women with Successfully Expectantly Managed Tubal Ectopic Pregnancies: A Retrospective Cohort Study. *PLoS One*. 2015;10(7):e0130598. doi: 10.1371/journal.pone.0130598.

13. Mavrelos D, Nicks H, Jamil A, Hoo W, Jauniaux E, Jurkovic D. Efficacy and safety of a clinical protocol for expectant management of selected women diagnosed with a tubal ectopic pregnancy. *Ultrasound Obstet Gynecol.* 2013;42(1):102-7. doi: 10.1002/uog.12401.
14. Rodrigues SP, de Burlet KJ, Hiemstra E, Twijnstra AR, van Zwet EW, Trimbos-Kemper TC, et al. Ectopic pregnancy: when is expectant management safe? *Gynecol Surg.* 2012;9(4):421-6. doi: 10.1007/s10397-012-0736-6.
15. Kirk E, Van Calster B, Condous G, Papageorgiou AT, Gevaert O, Van Huffel S, et al. Ectopic pregnancy: using the β -hCG ratio to select women for expectant or medical management. *Acta Obstet Gynecol Scand.* 2011;90(3): 264-72. doi: 10.1111/j.1600-0412.2010.01053.x
16. Bignardi T, Condous G. Does tubal ectopic pregnancy with hemoperitoneum always require surgery? *Ultrasound Obstet Gynecol.* 2009;33(6):711-5. doi: 10.1002/uog.6384.
17. Sabre A, Arul M. Tubal abortion case series: Important clinical findings found on diagnostic laparoscopy may preserve tubal function and future fertility. *J Case Rep Images Obstet Gynecol.* 2022;8:100110Z08AS2022.
18. Baggio S, Garzon S, Russo A, Ianniciello CQ, Santi L, Laganà AS, et al. Fertility and reproductive outcome after tubal ectopic pregnancy: comparison among methotrexate, surgery and expectant management. *Arch Gynecol Obstet.* 2021;303(1):259-68. doi: 10.1007/s00404-020-05749-2.
19. Kirk E, Condous G, Bourne T. The non-surgical management of ectopic pregnancy. *Ultrasound Obstet Gynecol.* 2006;27(1):91-100. doi: 10.1002/uog.2602.
20. Conte A, Sirico A, Parisi G, Parisi P, Cobellis L. Cervical twin ectopic pregnancy: case report and systematic review of literature. *Ital J Gynaecol Obstet.* 2023;35(2):229-37. doi: 10.36129/jog.2022.50.